Ownership and Use of Clinical Data. All Clinical Data, including raw data and results, generated under this Agreement shall be jointly owned by BioLineRx and Merck. Merck hereby assigns to BioLineRx an undivided one-half interest in, to and under the Clinical Data. BioLineRx hereby assigns to Merck an undivided one-half interest in, to and under the Clinical Data. If such assignment cannot or does not occur, including in circumstances where such assignment is precluded by law, the Party with the obligation to assign hereby grants the other Party a non-exclusive license, with the right to grant sublicenses and to assign its license rights to the Clinical Data to any Person, in each case without the consent of the granting Party and without any accounting to such Party; provided that each such sublicensee and assignee is bound in writing to comply with the terms of this Agreement that are relevant to use and exploitation of such Clinical Data. BioLineRx shall maintain the Clinical Data in its internal database; provided, however, that at all times during the Term BioLineRx shall grant Merck access to all Clinical Data and any portions of BioLineRx’s database that include Clinical Data. Notwithstanding the foregoing, and subject to the remaining provisions of this Section 3.8, [*] provided, however, that the foregoing shall not limit or restrict either Party’s ability to use the Clinical Data as may be necessary to comply with Applicable Law or as may be necessary to comply with its internal policies and procedures with respect to pharmacovigilance and adverse event reporting. For the avoidance of doubt, BioLineRx shall be free to use/share (including publish) data and results from the Study, including Clinical Data, which are solely related to the single-agent use of the BioLineRx Compound and are not related to the Combination, and which have been generated during the treatment period in which the BioLineRx Compound is used in monotherapy. Neither Party shall disclose the Clinical Data to a Third Party except to the extent that such Clinical Data has been published as provided in Section 12.2 [*].
Ownership and Use of Clinical Data. 3.8.1. All Clinical Data shall be ****. Company shall maintain the Clinical Data in its internal database; provided, however, that at all times during the Term, Company shall grant Merck access to all Clinical Data.
Ownership and Use of Clinical Data. Xxxxxx shall be the owner of all data and information generated by and in connection with the Clinical Studies and Xxxxxx initiated post-marketing studies including data analysis and clinical study reports (collectively, the “Clinical Data”) for use in the Field in the Xxxxxx Territory. Xxxxxx shall have the right during the Term to use all data from the Clinical Studies and Xxxxxx initiated post-marketing studies in connection with its performance of its obligations under this Agreement. Notwithstanding the foregoing, Kamada shall have the right to use all Clinical Data for use in registering, developing or marketing the Product in the Kamada Territory and, upon termination of this Agreement, except for early termination by Xxxxxx in accordance with Section 15.2(a) or Section 15.2(b), the Xxxxxx Territory, and Xxxxxx hereby grants to Kamada an irrevocable, perpetual, royalty-free license to all rights related to such data.
Ownership and Use of Clinical Data. 3.8.1. All Clinical Data shall be jointly owned by Antigen Express and Merck. Merck hereby assigns to Antigen Express an undivided one-half interest in, to and under the Clinical Data. Antigen Express hereby assigns to Merck an undivided one-half interest in, to and under the Clinical Data. If such assignment cannot or does not occur, including in circumstances where such assignment is precluded by law, the Party with the obligation to assign hereby grants the other Party a non-exclusive license, with the right to grant sublicenses and to assign its license rights to the Clinical Data to any Person, in each case without the consent of the granting Party and without any accounting to such Party. Antigen Express shall maintain the Clinical Data in its internal database; provided, however, that at all times during the Term, Antigen Express shall grant Merck access to all Clinical Data and any portions of Antigen Express’ database that include Clinical Data.
Ownership and Use of Clinical Data. Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
Ownership and Use of Clinical Data. Kamada shall be the owner of all data and information generated by and in connection with the Phase II/III and Phase IV Clinical Studies set forth in the above Sections 3.2(a)(i) and 3.2(a)(ii), while Kamada and Chiesi shall jointly own all data and information generated by and in connection with the other Clinical Studies, including the Additional Clinical Studies and Chiesi initiated post-marketing Clinical Studies including data analysis and Clinical Study reports (collectively, the “Clinical Data”). Starting from the Effective Date and afterwards on an ongoing basis during the Term, Kamada shall provide Chiesi with Clinical Data relating to the use of the Product in the Territory and Chiesi shall have the right, during the Term, to use all Clinical Data from the Clinical Studies in connection with the performance of its obligations under this Agreement. For the avoidance of doubt, all Clinical Data shall be regarded as Confidential Information of Kamada.
Ownership and Use of Clinical Data. 3.8.1. [***].
Ownership and Use of Clinical Data. 3.10.1. [***]. Collaborator shall maintain the Joint Clinical Data and any MSD Clinical Data in its internal database; [***].
Ownership and Use of Clinical Data. 3.8.1. All Clinical Data shall be jointly owned by FLX and Merck. Merck hereby assigns to FLX an undivided one-half interest in, to and under the Clinical Data. FLX hereby assigns to Merck an undivided one-half interest in, to and under the Clinical Data. [***]. FLX shall maintain the Clinical Data in its internal database; provided, however, that at all times during the Term, FLX shall [***] all Clinical Data [***].
Ownership and Use of Clinical Data. 3.8.1 All Clinical Data shall be jointly owned by Rexahn and Merck. [***].
